Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab +/- Cemiplimab in Advanced Malignancies
NCT03005782Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
Phase 1, open-label trial of fianlimab in malignant neoplasms (advanced stage) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Rate of dose limiting toxicities at 28 days, Rate of adverse events at 51 weeks and 6 more. Started Nov 2016; status: completed.
02
Drugs
fianlimab
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT03005782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005782.